Dermatologicals
Refine Search
Pharmaceutical
US commercial-stage biopharma Pelthos Therapeutics has secured a senior secured term loan facility of up to $50 million from Horizon Technology Finance (Nasdaq: HRZN), with $30 million funded at closing and up to $20 million available if certain milestones are met. 14 January 2026
Biotechnology
Spanish dermatology specialist Almirall is using its appearance at the 44th JP Morgan Healthcare Conference in San Francisco to set out an active 2026 clinical agenda, leaning into proof-of-concept work across immune-driven skin diseases and pushing one bispecific antibody into first-in-human testing. 14 January 2026
Pharmaceutical
Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-interleukin (IL)-15 antibody, TEV-'408. 12 January 2026
Biotechnology
The launch of USA-based Poplar Therapeutics has been announced, alongside a $50 million Series A financing led by SR One, Vida Ventures and Platanus. 8 January 2026
Biotechnology
Immune-mediated diseases specialist Alumis has announced positive top-line results from its Phase III ONWARD1 and ONWARD2 trials of envudeucitinib, a next-generation highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis. 7 January 2026
Biotechnology
In a slow news last week a mixed batch of clinical trials results featured. First, US biotech Ultragenyx announced disappointing Phase III results for its Osteogenesis Imperfecta (OI) candidate setrusumab, under development with Mereo BioPharm. Then InflaRx presented a new analysis of vilobelimab for pyoderma gangrenosum, and Pfizer disclosed a death in a long term Hympavzi study after thrombotic stroke. Also of note, after previous setbacks, the US Food and Drug Administration (FDA) granted approval for Vanda Pharmaceuticals’ motion sickness drug Nereus (tradipitant). 4 January 2026
Biotechnology
German drug developer InflaRx, which is developing anti-inflammatory therapeutics by targeting the complement system, has outlined multiple data analyses of the Phase III study for vilobelimab in pyoderma gangrenosum (PG). 30 December 2025
Biosimilars
Biocon Biologics, a fully integrated global biosimilars company and subsidiary of India’s Biocon Ltd, announced that it has secured full and exclusive global rights for Hulio (biosimilar adalimumab) from Fujifilm Kyowa Kirin Biologics (FKB). 29 December 2025
Pharmaceutical
Belgian biotech Galapagos has reported mixed Phase II results for GLPG3667, a selective TYK2 inhibitor, delivering a clear win in dermatomyositis but missing its primary endpoint in systemic lupus erythematosus. 22 December 2025
Biotechnology
Japanese drugmaker Takeda has announced positive topline results for two pivotal Phase III studies of zasocitinib (TAK-279), a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). 18 December 2025
Biotechnology
US biotech Nektar Therapeutics shares increased by 10% in pre-market trading following promising Phase IIb trial results. 17 December 2025
Pharmaceutical
Switzerland-based Roivant hosted an Investor Day in New York City today, highlighting its leadership with key pipeline updates and provided an update on the company’s strategy for long-term value creation, which saw the firm’s shares rise 6.6% to $21.58 in morning trading. 11 December 2025
Pharmaceutical
PsiThera has closed a $47.5 million series A round to advance oral therapies for immune and inflammatory diseases. The company also named former Seres Therapeutics chief executive Eric Shaff as chief executive. 11 December 2025
Pharmaceutical
Hong Kong-based Ascletis Pharma has announced that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor for the treatment of moderate-to-severe acne vulgaris, has been accepted by the China National Medical Products Administration (NMPA). 11 December 2025
Biotechnology
Privately-held UK biotech Relation Therapeutics has announced a multi-program, strategic collaboration with Swiss pharma giant Novartis to discover and advance novel targets for atopic diseases. 9 December 2025
Biotechnology
Shares of US clinical-stage biotech Kymera Therapeutic leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621. 8 December 2025
Pharmaceutical
Ireland incorporated Cosmo Pharmaceuticals saw its shares rise more than 3% to $91.80 yesterday, after it announced compelling top-line results from its two pivotal Phase III trials of clascoterone. 5 December 2025
Pharmaceutical
Sun Pharmaceutical Industries has announced the launch of its global innovative drug, Ilumya (tildrakizumab) in India for moderate-to-severe plaque psoriasis. 3 December 2025
Biotechnology
Shares of US clinical-stage biotech Q32 Bio were up a massive 150% at $5.48 by mid-morning after it revealed that it has sold its Phase II complement inhibitor, ADX-097, to Akebia Therapeutics. 1 December 2025
Biotechnology
China's National Medical Products Administration (NMPA) has approved Innovent Biologics’ Pecondle (picankibart injection), a recombinant anti-interleukin-23p19 subunit (IL-23p19) antibody, for the treatment of moderate-to-severe plaque psoriasis. 28 November 2025
Biotechnology
The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients with inadequate response to histamine-1 antihistamines (H1AH) and who are naive to anti- immunoglobulin-E (IgE) therapy for CSU. 25 November 2025
Pharmaceutical
Australian drugmaker Mayne Pharma last week revealed it has been notified by USA-based Cosette Pharmaceuticals that it had received written notice from the Foreign Investment Review Board (FIRB) stating that the Treasurer has objected to the proposed Scheme. 24 November 2025
Biotechnology
Regeneron Pharmaceuticals has announced that the European Commission (EC) has approved the PD-1 inhibitor Libtayo (cemiplimab) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. 20 November 2025
Pharmaceutical
The race to find a new treatment for hair loss hotted up last month with two mega funding rounds for Pelage Pharmaceuticals and Veradermics. The deals also demonstrated biopharma’s growing interest in consumer-focused prescription products. 14 November 2025
Pharmaceutical
Spanish dermatology specialist Almirall has announced its financial results for the first nine months of 2025, presenting a positive pictured that investors evidently acknowledged as shares in the firm looked set to close 3% higher on Monday. 10 November 2025
Pharmaceutical
Biopharma company Pelthos Therapeutics has acquired the US commercialization rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera and Ferrer Internacional. 7 November 2025
Pharmaceutical
Belgian biopharma company UCB has announced a leadership reshuffle, effective January 1, 2026, as part of a plan to reinforce cross-functional collaboration and sustain growth. 7 November 2025
Biosimilars
South Korea’s Samsung Bioepis. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of Pyzchiva, a biosimilar to J&J’s Stelara (ustekinumab), in Europe. The terms of the agreement remain confidential. 6 November 2025
Biotechnology
Swiss inflammatory diseases specialist MoonLake Immunotherapeutics has announced the pricing of a $75 million underwritten offering. 6 November 2025
Pharmaceutical
Privately-held Danish dermatology specialist LEO Pharma today announced that the UK’s National Institute for Health and Care Excellence (NICE) has issued Technology Appraisal Guidance (TAG) recommending the reimbursement of Anzupgo (delgocitinib) cream. 5 November 2025
Pharmaceutical
Swiss biopharma Relief Therapeutics today announced positive results from its pivotal bioequivalence clinical study evaluating RLF-OD032, Relief’s innovative and highly concentrated liquid formulation of sapropterin dihydrochloride, for the treatment of phenylketonuria (PKU). 29 October 2025
Pharmaceutical
Italian biotech MimeTech has announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to its investigational drug udonitrectag lysine for the treatment of diabetic foot ulcers (DFU). 29 October 2025
Pharmaceutical
Shares in Swiss pharma giant Novartis closed 4% lower Tuesday after the firm reported its third-quarter 2025 financial results. 29 October 2025
Pharmaceutical
US biopharma company Incyte has announced new data from the Phase IIIb TRuE-AD4 study evaluating the efficacy and safety of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). 28 October 2025
Biotechnology
Oncolytic immunotherapies specialist Replimune Group has announced that the US Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen. 21 October 2025
Pharmaceutical
USA-based clinical-stage dermatology start-up Veradermics has announced the completion of an oversubscribed $150 million Series C financing. 17 October 2025
Biotechnology
Los Angeles, USA-based biotech Pelage Pharmaceuticals has announced the close of a $120 million Series B financing. 16 October 2025
Pharmaceutical
US healthcare giant Johnson & Johnson has announced its third-quarter financial results and guidance for the rest of 2025. 14 October 2025
Biotechnology
M&A news last week featured Denmark-based Genmab’s plans to expand its portfolio with an up to $8 billion acquisition of Dutch biotech Merus along with its cancer candidate petosemtamab. On the research front, Switzerland’s MoonLake Immunotherapeutics saw its shares plunge 90% on disappointing Phase III trial results for its inflammatory disease candidate sonelokimab, and US biotech giant Amgen released new Phase III data on its cardiovascular drug Repatha. Also of note, US pharma giant Pfizer became the first drugmaker to strike a deal with government to lower medicine prices and join President Donald Trump’s Trump\Rx.gov program. 5 October 2025
Biotechnology
The US Food and Drug Administration (FDA) has approved Rhapsido (remibrutinib) as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. 1 October 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze